OBJECTIVES: PEGylated interferon beta-1a (PEG-IFN beta-1a) is being developed for the treatment of relapsing-remitting multiple sclerosis

Content Provider	Semantic Scholar
Copyright Year	2012
Abstract	the treatment of relapsing-remitting multiple sclerosis (MS). PEGylated drugs are commonly used in other therapeutic areas, including oncology and hepatitis, but none are currently approved for MS. This study was conducted to gain a better understanding of the published humanistic and patient quality of life benefits of PEGylated drugs currently available for the treatment of other diseases. METHODS: A comprehensive search of medical literature published between 1985 and 2010 was conducted using PubMed/MEDLINE and supplemental searches. Reviewed references were prospective or retrospective studies reporting the tolerability, healthrelated quality of life (HRQOL), convenience, compliance, and patient preferences associated with PEGylated drugs. Only studies comparing PEGylated drugs to their corresponding non-PEGylated counterparts in the same therapeutic area were included in the analysis. RESULTS: Fifty-nine articles and 12 conference abstracts were reviewed. Eleven PEGylated drugs were identified, 6 of which had corresponding non-PEGylated counterparts. All 6 of these PEGylated drugs were administered less frequently than their non-PEGylated counterparts yet exhibited similar or greater efficacy, along with greater patient convenience. PEGylated drugs were generally tolerated as well as or better than their non-PEGylated counterparts. In HRQOL studies, patients who received PEGylated drugs reported better HRQOL than those receiving non-PEGylated drugs across a broad spectrum of domains, as well as in global HRQOL scores. For studies measuring quality-adjusted life-years (QALYs), PEGylated drugs were reported to produce more QALYs than their nonPEGylated counterparts. While few studies have evaluated patient medication compliance and patient preference/satisfaction, the published results of these studies also favor PEGylated drugs. CONCLUSIONS: PEGylated drugs are reported to be tolerated at least as well as their non-PEGylated counterparts and to be associated with higher HRQOL and greater patient preference/satisfaction, convenience, and compliance. PEG-IFN beta-1a may offer similar benefits to patients with MS.
File Format	PDF HTM / HTML
Alternate Webpage(s)	https://core.ac.uk/download/pdf/82425035.pdf
Language	English
Access Restriction	Open
Content Type	Text
Resource Type	Article